Evotec will access Indivumed's IndivuType multi-omics cancer database to discover and develop new precision therapeutics for colorectal cancer.
The companies will use their respective technologies to optimize the cannabinoid profiles and other traits of different cannabis varieties.
A NorthShore University HealthSystem and Color pilot picked up pathogenic variants in nearly 9 percent of unselected individuals with a hereditary cancer gene test.
The test will be designed to detect a protein biomarker in aqueous humor that can be used to determine the severity of glaucoma and to make treatment decisions.
LUNGevity will promote the donation of excess lung cancer tissue and fluid samples to boost the Broad's efforts to develop next-generation research models.
Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.
The five-year deal, which is being funded by UCB, will focus in particular on epilepsy patients who do not respond to currently available treatments.
The R&D collaboration will examine a Western Digital theory that moving computational power closer to large genomic datasets can speed up analysis.
LunaDNA parent company LunaPBS will combine its technology platform with Genetic Alliance's PEER system to advance patient-centric research.
The partners said they have agreed to work together on projects in a range of diseases, as well as establish research alliances with groups in China and Africa.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.